Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis

A legfontosabb adatok

Ki végzi
NexEos Diagnostics, Inc.
Hol
Chicago, Philadelphia és Salt Lake City (Egyesült Államok)Mind a 3 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
34 fő vett részt
Kezdés
2023. jan. 20.
Befejezés
2025. máj. 22.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • NDX-3315
  • NDX-3324
  • SPECT/CT Imaging
A regiszteradat frissítve
2026. május 14.

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 6 feltétel megnézéseKevesebb

Ki vehet részt

  • Healthy Participants:; Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and electrocardiogram (ECG) assessment
  • EoE Participants:; Documented diagnosis of EoE (based on prior endoscopy with biopsies showing eosinophils ≥15 / HPF); AND; History (by patient report) of recurrent dysphagia and/or other related EoE symptoms (with intake of solids off anti-inflammatory therapy) prior to screening; dysphagia is defined as trouble swallowing solid food, or having solid food stuck, by patient report

Ki nem vehet részt

  • Prior/Concomitant Therapy:; Participant who is on anticoagulation therapy that, in the investigator or Medical Monitor's opinion, cannot safely come off medication; Use of chronic aspirin (with the exception of low-dose aspirin as long as the dose remains stable and not increased while on study), nonsteroidal agents, or anti-coagulants within 2 weeks prior to screening; Use of systemic corticosteroids within 3 months or swallowed topical corticosteroids within 6 weeks prior to Screening visit; Participant is being treated with systemic immunosuppression, carafate (sucralfate), or investigational agent of any kind within less than 3 months or 5 half-lives, whichever is longer, prior to Screening visit (this also includes investigational formulations of marketed products)
  • Medical Conditions:; Participant with presence of any other disease of the GI tract, including cancer, autoimmune esophageal disease, GERD which is symptomatic or uncontrolled, Barrett's esophagus, eosinophilic gastritis, enteritis, colitis, or proctitis; inflammatory bowel disease; or celiac disease. Known motility disorder of esophagus; achalasia or suspicion thereof; Sleep apnea, if considered by the investigator a concern for the endoscopic procedure; History of recurrent aspiration pneumonia; History of bleeding disorders, liver cirrhosis or esophageal varices; A current malignancy or previous history of cancer in remission for less than 5 years prior to Screening (participants will not be excluded if they had localized carcinoma of the skin that was resected for cure); Participant with a Body Mass Index >40 m2/kg or inability to undergo a CT (or SPECT scan) due to weight limitations; Participant is pregnant or nursing
  • Diagnostic Assessments:; Evidence of clinically significant abnormality in the hematological and biochemical assessments at Screening Visit, specifically: International Normalized Ratio (INR) >1.4; platelet count <80,000/μL and creatinine level >2 mg/dL; ECG: QTcF ≥450 msec for males and QTcF ≥470 msec for females at the time of screening
  • Other Exclusion Criteria:; Any condition that would not permit adequate biopsies of the esophagus (e.g., esophageal varices, significant stricture precluding passage of a 9 mm endoscope, known allergy to sedative used for endoscopy); Healthy Participants Only: A history or current diagnosis of allergic diseases (Should be discussed with Medical Monitor and PI to decide whether exclusionary), autoimmune disease, chronic rhinosinusitis or serum immunoglobulin E (IgE) level ≥100 kU/L. On any medications including NSAIDS and any over the counter (OTC) medications unless it is birth control or acne medications with the exception of Accutane, or if deemed acceptable to use by Medical Monitor and PI

Helyszínek itt: Egyesült Államok

  • Northwestern UniverisityChicago, Egyesült Államok
  • University of PennsylvaniaPhiladelphia, Egyesült Államok
  • University of UtahSalt Lake City, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

An open-label phase 2 study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 and NDX-3324 in healthy participants and patients with eosinophilic esophagitis (EoE).

A vizsgálat 2 csoportja

  • Participants Receiving NDX-3315A vizsgált kezelés

    Participants receive NDX-3315 (delivered via oral syringe at \~ 1.5 mL per minute) using Regimen 5 (5 sips administered over approximately 5 minutes) or Regimen 10 (10 sips administered over approximately 10 minutes), followed by SPECT/CT imaging. Both healthy participants and participants with EoE are included.

    Kezelés: NDX-3315 és SPECT/CT Imaging

  • Participants Receiving NDX-3324A vizsgált kezelés

    Participants receive NDX-3324 (delivered via oral syringe at \~ 1.5 mL per minute) using Regimen 10 (10 sips administered over approximately 10 minutes) in a sitting reclined position, followed by SPECT/CT imaging. Both healthy participants and participants with EoE are included.

    Kezelés: NDX-3324 és SPECT/CT Imaging

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Open-label Phase 2 Study Assessing the Safety, Tolerability and Preliminary Diagnostic Performance of a Radioactive Imaging Agent, NDX-3315 and NDX-3324, in Healthy Adult Participants and Patients With Eosinophilic Esophagitis
A regiszteradat frissítve
2026. május 14.